Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q13217

UPID:
DNJC3_HUMAN

ALTERNATIVE NAMES:
Endoplasmic reticulum DNA J domain-containing protein 6; Interferon-induced, double-stranded RNA-activated protein kinase inhibitor; Protein kinase inhibitor of 58 kDa

ALTERNATIVE UPACC:
Q13217; Q86WT9; Q8N4N2

BACKGROUND:
The protein kinase inhibitor of 58 kDa, a key player in cellular stress responses, regulates EIF2AK4/GCN2 kinase activity under ER stress, hypothermic, and amino acid starving stress conditions. It inhibits EIF2AK2/PKR autophosphorylation and EIF2AK3/PERK activity, playing a significant role in protein synthesis regulation.

THERAPEUTIC SIGNIFICANCE:
Linked to a severe disease with symptoms including juvenile diabetes and neurodegeneration, the study of this protein offers a promising avenue for developing treatments targeting these debilitating conditions. Its multifaceted role in biological systems makes it an intriguing subject for scientific inquiry and drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.